Bristol Myers Squibb (CELG-RI) Short-term Investments (2009 - 2026)

Bristol Myers Squibb has disclosed Short-term Investments across 18 years of filings, most recently posting $912.0 million for Q1 2026.

• In Q1 2026, Short-term Investments rose 0.55% year-over-year to $912.0 million; the TTM figure through Mar 2026 stood at $912.0 million (up 0.55% YoY), while the FY2025 annual figure was $464.0 million, down 9.55% from the prior year.
• Short-term Investments advanced to $912.0 million in Q1 2026, from $464.0 million in the prior quarter.
• Over the last five years, Short-term Investments for CELG-RI reached as high as $2.6 billion in Q1 2022 and fell as low as $130.0 million in Q4 2022.
• The 5-year median for Short-term Investments is $513.0 million (2024), against an average of $799.9 million.
• Annual changes were most pronounced in 2022 — Short-term Investments tumbled 95.65% — and 2023, when it surged 527.69%.
• A 5-year view of Short-term Investments shows it stood at $130.0 million in 2022, then surged by 527.69% to $816.0 million in 2023, then slumped by 37.13% to $513.0 million in 2024, then retreated by 9.55% to $464.0 million in 2025, then soared by 96.55% to $912.0 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $912.0 million, $464.0 million, and $776.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.